- Medicine Name: Vabomere
- Generic Name: Meropenem and Vaborbactam
- Dosage Form & Strength: Sterile powder for constitution in single-dose vials containing meropenem 1 gram (equivalent to 1.14 grams of meropenem trihydrate) and vaborbactam 1 gram.
- Manufactured By: The Medicines Company
Vabomere (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, used for the treatment of patients aged 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
Note: Prescribing Vabomere medicine in the absence of a proven or strongly suspected bacterial infection is unlikely to offer benefit to the patient and may increase the probability of drug-resistant bacteria.
Recommended Dosage: Medicine Vabomere is supplied as a dry powder in a single-dose vial that must be constituted and further diluted before intravenous infusion as outlined below. This medication does not contain preservatives. Aseptic technique must be considered for constitution and dilution.
The recommended dosage is 4 grams (meropenem 2 grams and vaborbactam 2 grams) administered every 8 hours by intravenous (IV) infusion over three hours in patients aged 18 years and older with an estimated glomerular filtration rate (eGFR) greater than or equal to 50 mL/min/1.73m². The time-span of treatment is for up to two weeks (14 days).
Dosage adjustment is recommended in those with renal impairment who have an eGFR less than 50 mL/min/1.73m². The recommended dosage in patients with varying degrees of renal function is as follows:
- Vabomere 2 grams (meropenem 1 gram and vaborbactam 1 gram) administered every 8 hours by intravenous (IV) infusion with an estimated glomerular filtration rate (eGFRa) 30 mL/min/1.73m² to 49 mL/min/1.73m².
- Vabomere 2 grams (meropenem 1 gram and vaborbactam 1 gram) administered every 12 hours by intravenous (IV) infusion with an estimated glomerular filtration rate (eGFRa) 15 mL/min/1.73m² to 29 mL/min/1.73m².
- Vabomere 1 gram (meropenem 0.5 grams and vaborbactam 0.5 grams) administered every 12 hours by intravenous (IV) infusion with an estimated glomerular filtration rate (eGFRa) less than 15 mL/min/1.73m².
For those with changing renal function, monitor serum creatinine concentrations and eGFR at least daily and adjust the dosage accordingly.
Meropenem and vaborbactam are removed by hemodialysis. For those maintained on hemodialysis, administer Vabomere after a hemodialysis session.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.